iRhythm Technologies (IRTC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Voting matters and shareholder proposals
Election of nine directors to serve until the 2027 annual meeting or until successors are elected and qualified.
Approval of the 2026 Equity Incentive Plan.
Approval of the Amended and Restated Certificate of Incorporation to remove the pass-through voting provision.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve named executive officer compensation.
Board of directors and corporate governance
Nine director nominees are presented for election, including C. Noel Bairey Merz, M.D., Quentin Blackford, Bruce Bodaken, Karen Ling, Karen McGinnis, Kevin O'Boyle, Jason Patten, Abhijit Talwalkar, and Brian Yoor.
Executive compensation and say-on-pay
Advisory vote is proposed to approve compensation for named executive officers.
Latest events from iRhythm Technologies
- Annual meeting to vote on directors, equity plan, auditor, and executive pay amid strong growth and ESG focus.IRTC
Proxy filing17 Apr 2026 - AI-driven cardiac monitoring, record 2025 revenue, and global expansion fuel strong growth.IRTC
44th Annual J.P. Morgan Healthcare Conference12 Apr 2026 - Proxy covers director elections, new equity plan, auditor change, and strong pay-for-performance.IRTC
Proxy filing6 Apr 2026 - Record 2025 growth, first positive net income, and strong 2026 outlook with margin expansion.IRTC
Q4 202519 Feb 2026 - Long-term monitoring leads market growth, with new products and partnerships fueling 2025 momentum.IRTC
2024 Truist Securities MedTech Conference3 Feb 2026 - Q2 revenue up 19.3% to $148M; guidance raised amid strong demand and ongoing regulatory risks.IRTC
Q2 20242 Feb 2026 - 2024 revenue guidance of $578–$588M reflects global growth in AI-driven cardiac monitoring.IRTC
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - BioIntelliSense deal, FDA remediation, and MCT launch set stage for growth in 2025.IRTC
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Regulatory remediation and international expansion position the business for accelerated growth.IRTC
2024 Wells Fargo Healthcare Conference22 Jan 2026